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Background: Staphylococcus aureus bacteraemia (SAB) is associated with relatively high
risk of complications and high levels of mortality. Internationally, SAB management
guidelines lack consensus and especially so regarding oncology patients. This is likely a
reflection of insufficient randomised control trials (RCT) and the diversity of SAB patient
populations. However, there are 2011 guidelines recommending a minimum of 14 days of
appropriate IV antibiotic therapy for SAB.
Objective: We wished to determine whether our practice of shortened duration of
intravenous antimicrobial therapy in favour of oral administration proved as effective as
recommended guidelines in a mixed oncology patient cohort.
Methods: Retrospective review of patient records that included any SAB episode among
oncology patients from January 2002 to December 2015. Medical chart reviews were
undertaken to determine patient demographics, clinical management & antimicrobial
therapy, duration of stay, presence of a central venous catheter (CVC) and outcome.
Results: Our CVC removal rate was just 73% in SAB where CVC was the identified source of
infection, with an attributable mortality rate (<4%) far lower than would be expected.
Antimicrobial therapy durations were considerably lower (10 days) than current recom-
mendations of 14 days IV therapy. The recurrence rate of 15% was also significantly lower
than has been reported previously.
Conclusions: Our observations contribute new insights concerning the management of SAB
in oncology patients. Our findings suggest that therapeutic approaches should perhapsical School University of
Dunne).
Elsevier Ltd on behalf of The Healthcare Infection Society. This is an open access article
ivecommons.org/licenses/by-nc-nd/4.0/).
C.P. Dunne et al. / Infection Prevention in Practice 2 (2020) 1000372remain individualised and reflective of patient characteristics taking into consideration
the complex nature of oncology patients.
ª 2020 The Authors. Published by Elsevier Ltd
on behalf of The Healthcare Infection Society. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Staphylococcus aureus bacteraemia (SAB) is associated with
relatively high risk of complications and high levels of mortal-
ity. A 2014 meta-analysis of prospective observational studies
internationally found a 90-day mortality of almost 30%, con-
firming previous reports [1]. In that context, our study was
conducted in Ireland, during a period in which incidence of SAB
declined from 0.346 per 1000 Bed Days Used (BDU) in 2004, to
0.271 in 2018 [2]. Encouragingly, while methicillin-resistant
Staphylococcus aureus (MRSA) bacteraemia accounted for
23.8% of episodes in 2011 and decreased to 19.5% in 2014, that
number had further declined to only 12.8% in 2018.
Internationally, SAB management guidelines lack consensus
[3]. This is likely a reflection of insufficient randomised control
trials (RCT) and the diversity of SAB patient populations [4].
However, there are 2011 guidelines recommending a minimum
of 14 days of appropriate antibiotic therapy for SAB, with more
prolonged courses where there is evidence of persistent deep-
seated infection [5,6]. An Icelandic population-based study
defined appropriate antibiotic therapy duration as>/¼ 10 days
IV therapy with an appropriate agent for uncomplicated
infection and >/¼ 24 days for complicated infection, and
demonstrated lower relapse rates and mortality [7]. Notably,
those guidelines have evolved considerably from those sug-
gested in a 1982 paper of 4e6 weeks antibiotic therapy for SAB
[8]. Choice of appropriate antimicrobial therapy is also chal-
lenging, due somewhat to the aforementioned paucity of
definitive RCTs and the emerging threat of vancomycin resist-
ant S. aureus (VRSA). Currently, ß-lactams offer relatively
rapid, long-term clearance and are seen as more effective than
glycopeptides [9,10]. Cefazolin (a cephalosporin) is deemed
non-inferior to penicillins and may be a useful alternative to
reduce dosage frequency [11]. Aminoglycosides, specifically
gentamycin, are frequently co-administered with ß-lactams for
a presumed synergistic effect despite insufficient evidence in
the clinical setting [5]. Two RCTs have reported that oral
administration of some antibiotics can have efficacy equivalent
to IV administration [12,13]. Therefore, our study attempts in
part to provide new insight regarding this latter approach.
Irrespective of duration and chosen antimicrobial agent,
source control is widely acknowledged to be an important
aspect of treating SAB, with failure to remove a source of
ongoing infection often precipitating failure of blood steri-
lisation. This is particularly relevant to intravascular devices
such as central venous catheters (CVC), which for instance
represent approximately one third of healthcare-associated
infections in the United States [14]. Strong associations have
been demonstrated between failure to remove these, relapse
of infection and risk of mortality [14,15], conversely, prompt
removal has been associated with uncomplicated bacteraemia
(i.e., no secondary deep-seated focus of infection and no
recurrence within 3 months) [16]. Other factors associated
with poor outcomes include persistent bacteraemia, septicshock, co-morbidities including cancer and community
acquisition of infection [17].
There are few data regarding SAB in specific oncology pop-
ulations. SAB occurring in oncology patients is overwhelmingly
CVC-associated as many of these patients have long-term
tunnelled CVCs in situ to facilitate administration of chemo-
therapy [18]. Mortality associated with SAB in oncology
patients has been reported as being as high as 33%, higher than
mortality associated with other pathogens in this population
[19]. A Spanish study of neutropenic cancer patients with SAB
found that 14% (4 of 28) of patients had septic metastases
identified [18], while a 2007 United States study described a
high incidence of CVC-related SAB complications with 19% of
implicated patients having intravascular complications [20].
Framed this way, German guidelines concerning catheter-
related bloodstream infection in haematology/oncology
patients recommend CVC removal in all patients with SAB,
citing high relapse rates if retention is attempted [21]. An
earlier retrospective review (2001) of CVC-associated SAB
found higher mortality with shorter duration of treatment [22]
while the US study mentioned above reported that removal of
the catheter within 3 days was associated with a lower relapse
rate [20]. More recently, an important large observational
study across several centres in France revealed a SAB compli-
cation rate of 36% [23]. Subgroup analysis found an endo-
carditis rate of 11.9% in non-nosocomial SAB. The occurrence of
CVC-related septic thrombosis with associated deep-seated
infections has been described in association with SAB in can-
cer patients and a higher relapse rate demonstrated with
shorter treatment duration (14 days versus >14 days) in this
group, highlighting the importance of identifying deep-seated
foci in these patients and adjusting treatment duration
accordingly [24].
Our study attempted to elucidate the complexity of SAB
amongst oncology patients, and specifically with regard to the
difficulty of CVC management in SAB. More specifically, we
performed a retrospective review of oncology patient records
with respect to CVC SAB acquisition (from Jan 2002 until
December 2015) to determine whether acceptable patient
outcomes were achieved through local practice of prompt
catheter removal and relatively short duration of IV antibiotic
administration before switch to oral delivery.
Methods
Study design
Retrospective review of patient records that included any
SAB episode among University Hospital Limerick (Ireland)
oncology patients from January 2002 to December 2015. Med-
ical chart reviews were undertaken to determine patient
demographics, clinical significance of microbiological result,
clinical management & antimicrobial therapy, duration of stay,
presence of a CVC and outcome. The laboratory information
C.P. Dunne et al. / Infection Prevention in Practice 2 (2020) 100037 3system (LIS) was interrogated for data concerning blood culture
procurement, time to positivity and antibiotic sensitivity pro-
files. Only anonymised data are presented.
Setting
The Mid Western Cancer Centre is based at UHL, a 480-bed
hospital in the mid-west of Ireland that is the regional ter-
tiary referral centre for a combined population of 400,000 and
which has been the site of notable hospital acquired infection
outbreaks [25e27] and subsequent innovations in patient
management [28]. The Mid Western Cancer Centre is one of 8
designated cancer centres in the Republic of Ireland and pro-
vides specialised breast and colorectal cancer surgery services
as well as a medical oncology and radiotherapy services.
Definitions
An episode of SAB was defined as the presence of systemic
symptoms including a temperature>38 C or<36.5 C, apnoea,
tachycardia, bradycardia, hypotension, confusion or agitation
along with at least one positive blood culture. Resolution was
determined by a subsequent sterile blood culture with a
reversal of symptoms.
Reccurrence was defined as the reestablishment of systemic
symptoms with at least one positive blood culture following a
period of resolution (>48 h). In this setting, complications were
defined as SAB recurrence or the presence of deep-seated foci
that were attributed to SAB infection. A CVC associated SAB
was defined as the presence of the same bacteria in a given
blood culture being successfully cultured from a catheter line
tip (>15 colony forming units (Maki rolling method)) or the
surrounding skin insertion site, differential time to positivity
with same pathogen >2 h between CVC and peripheral simul-
taneously drawn blood cultures sets, or symptomatic
improvement within 48 hours of removal of the CVC in the
setting of associated sterile peripheral blood cultures. Neu-
tropaenia was defined as a neutrophil count <1.0 x109/L with
neutrophilia being defined as a neutrophil count >7.5x109/L.
Laboratory methods
Biomerieux BacT/Alert 3DTM was used for blood culture
incubation. Staphylococcus aureus species were identified
using Pastorex Staph-Plus latex agglutination (Bio-Rad, Marnes-
la-Coquette, France) and DNase agar (LIP Fannin, Galway,
Ireland). Since July 2012 mass spectrometry was available for
confirmation (MALDI-ToF MS, Bruker Daltonik, Bremen, Ger-
many). Antimicrobial susceptibility testing was performed
using Sensititre broth microdilution (TREK Diagnostic Systems
Inc., Cleveland, USA) and oxacillin E-test (BioMe´rieux, AB Bio-
disk, Solna, Sweden).Table 1
Management of complicated vs. uncomplicated CVC-associated SAB in
Number of episodesa CVC removed within 48 h (%) M
C
Complicated 19 5 (26.3)
Uncomplicated 26 5 (19.2)
a Data were incomplete for 3 episodes.Data analysis
Data were stored and analysed using Microsoft Excel 2016.
Results
Over the 14-year period from January 2002 to December
2015, 53 episodes of SAB occurred in 45 patients. All episodes of
SAB in our dataset were deemed to be of clinical significance.
Females accounted for 62% (n¼28) of episodes. Themedian age
of initial episode was 52 (range 21e73). The spectrum of
recorded malignancies closely reflected Irish national preva-
lence data. [29] Among the cohort, solid tumours accounted for
87% (n¼39) of malignancies. Breast carcinoma was most fre-
quent (40%, n¼18), followed by colorectal (27%, n¼12), testis
(7%, n¼3), and oesophagus (4%, n¼2). The primary malig-
nancies in the remaining patients (8%, n¼4) were gastric, lung,
ovarian, and prostatic. Malignancy data were unavailable for
one case and the rest of patients had miscellaneous malig-
nancies (11% n¼5). This cohort of patients comprised a mixture
of those receiving treatment for either primary disease or for
relapse/progression of disease at the time of the initial SAB
diagnosis.
Risk factor stratification
In retrospect, five of the patients who had a CVC-related
bloodstream infection could have been identified as at risk of
SAB prior to CVC insertion. Our review of case notes revealed a
previous Hickman removed because of a CVC-associated
coagulase negative Staphylococcus bacteraemia (CoNS) (1
patient); Peripheral Venous Catheter (PVC) phlebitis (1
patient); post-operative wound infection (1 patient); local
infection at the site of a previous CVC (peripherally inserted
central catheter) (1 patient)) and Hickman (the same patient));
or skin rash at the time of line insertion (1 patient). Fourteen
further patients experienced problems with CVC prior to the
onset of SAB; in 1 case, the line insertion took 2 attempts due to
a faulty guidewire (1 patient), while fever and rigors developed
immediately after the CVC was inserted (1 patient), albeit that
bacteraemia was not documented until 7 days later. The
remaining twelve patients had documented CVC exit-site
infection (one several months prior to the bacteraemia), the
patient had a documented CVC exit-site infections a number of
months prior to the new CVC insertions. Of this cohort, 50%
(n¼6) had received oral antibiotics. The remaining patient had
a documented wide-spread skin rash.
SAB source identification and subsequent management
A CVC was in situ at the time of SAB diagnosis in 96% (n¼51)
of episodes in 43 patients and was deemed the source in 90%oncology patients
ean days from SAB to
VC removal (Range)
Mean days IV antibiotic
with activity (Range)
Mean days targeted
IV antibiotic (Range)
3.7 (0e13) 5.1 (0e14) 2.4 (0e12)
4.1 (0e13) 4.5 (0e10) 1.6 (0e10)
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C.P. Dunne et al. / Infection Prevention in Practice 2 (2020) 1000374(n¼48) of SAB episodes (40 patients). 4% (n¼2) had a chest
source and 6% (n¼3) were undetermined. Of those episodes
implicating a CVC as source, 69% (n¼33) were confirmed via
positive swab culture from CVC site, 15% (n¼7) were confirmed
by isolation of S. aureus from CVC tip, 6% (n¼3) were confirmed
by differential time to positivity, and 8% (n¼4) were confirmed
on grounds of clinical evidence of line site infection. Finally, 2%
(n¼1) were assumed to be line source as only cultures procured
from the line were positive while peripheral cultures were
sterile.
Of the 48 episodes with a CVC source, 35 episodes involved
tunnelled CVCs with an external port and 9 episodes involved
tunnelled CVCs with a subcutaneous port. A single peripherally-
inserted central catheter (PICC) was also implicated. Inter-
ventional radiology assisted line placement in 36 cases, while
17% (n¼8) were placed in theatre and only one (1) on the ward.
The latter nine placements were most likely performed by
registrar physicians.
In 94% (n¼45) of episodes the patient was documented as
systemically unwell at the time of recorded bacteraemia. In
43% (n¼23) of patients, neutrophilia was recorded at the time
of documented bacteraemia, 27% (n¼14) of patients were
neutropenic at the time of the bacteraemia and in 30% (n¼16)
the neutrophil count was within range. Following SAB diagnosis
and therapy, documented sterile blood cultures were obtained
in 71% (n¼37) and not obtained in 29% (n¼15), data were
unavailable for 1 episode. In the 37 episodes where sterile
blood cultures were obtained, the mean number of days from
the initial positive blood culture to documented sterility was
4.3.
Regarding CVC source episodes, the median number of days
from CVC insertion to SAB diagnosis was 49 (median 33, range
7e206). In 87% (n¼46) of episodes, the CVC had been used to
administer chemotherapy prior to SAB onset. Themean number
of days from the most recent device access for chemotherapy
to SAB onset was 15 (median 11, range 1e87). Of the 48 CVC
source episodes, the offending line was removed in 73% (n¼35)
although data were incomplete for 3 of these episodes (avail-
able data are reflected in Tables where possible). Of the 45
episodes, 19 were deemed complicated (as per earlier defi-
nition). However, evidence of complications did not correlate
with meaningfully quicker removal of CVCs or longer durations
of IV antibiotic therapy (Table 1).
Where the CVC was removed (32 episodes with complete
data), the median number of days from SAB diagnosis to line
removal was 3 (range 0e15). These episodes were associated
with higher numbers of systemic symptoms and abscesses/
thromboses, but there was no statistical difference in sub-
sequent recurrence of SAB between these cases and the 27%
(n¼12) episodes where the CVC was left in situ and attempts
made to salvage the insertion (Table 2), 13% versus 25%
respectively. However, statistical difference may not have
been achieved due to the relatively low numbers of patients
involved. Analysis of episodes where CVCs were removed
within 48 hrs of SAB diagnosis rather than later than 48 hrs
identified earlier removal of CVC where median duration of IV
therapy approximated 7 days or, in other words, where prior
therapy over 7 days had failed to achieve clinical benefit
(Table 3). Notably, with both approaches (irrespective of evi-
dence of multifocal infection or line abscesses) the median
time to achieving sterile blood cultures following removal of
the CVC was 2 days. This indicates that irrespective of when the
Table 3
Characteristics and Management of CVC-associated SAB: CVC removed within 48 hours vs. not removed within 48 hours or not removed at
all
Number
of episodes
Systemic
symptoms (%)
Neutropenia
(%)
Line site
abscess (%)
Deep venous
thrombosis (%)
Evidence of
multifocal
infection (%)
Median days IV
antibiotic with
activity (Range)
Median days targeted
IV antibiotic
(Range)
CVC removed
within 48 h
10 10 (100) 3 (33.3) 2 (20) 1 (10) 0 7 (2e14) 0 (0e12)
CVC not removed
within 48 h
32 28 (87.5) 7 (21.8) 2 (6.2) 1 (3.1) 2 (6.2) 4 (0e13) 0 (0e6)
C.P. Dunne et al. / Infection Prevention in Practice 2 (2020) 100037 5CVC is removed antimicrobial efficacy can be consistent (albeit
that further larger cohort studies are need to verify this),
although the single death associated with SAB per se was
observed in the patient cohort that had delayed CVC removal
(Table 4) (Table 5).
Antimicrobial resistance and duration of antibiotic
therapy
Resistance amongst isolates was infrequent; 92% (n¼49)
sensitive to flucloxacillin. MRSA accounted for 8% (n¼4) of
isolates. None of the isolates were VRSA. Empiric antimicrobial
therapies including either monotherapy piperacillin-
tazobactam or pipercillin-tazobactam with gentamicin were
administered. The mean number of therapy days with either IV
or PO antibiotics likely to have had activity against the SAB was
10.2 (1 episode where antibiotics were discontinued to priori-
tise palliative care was excluded). The mean number of days of
IV antibiotics likely to have had activity against the SAB was 4.9
(exclusions as before). The mean number of days of optimal
targeted antibiotic therapy (agent/route/dose) was 1.5
(exclusions as before). A combination of piperacillin-
tazobactam 4.5 g TDS IV with flucloxacillin 1 g QDS IV was
deemed adequate therapy by the clinical oncology team
(wishing to negate risk of polymicrobial infection) rather than
monotherapy high dose IV flucloxacillin. Irrespective of
whether CVCs were removed within 48 hrs or not, antimicrobial
treatment durations were markedly lower than the 14 days of
intravenous therapy recommended by current guidelines.
SAB recurrence
The overall recurrence rate in our 45 patient cohort was
15.6% (n¼7 episodes in 7 patients). The mean time to recur-
rence was 93 days. In one excluded case, SAB recurrence
occurred almost 8 months later and, as the second isolateTable 4
Outcomes of CVC-associated SAB: CVC removed within 48 hours vs. no
Number
of episodes
Persistently positive
blood culture
at  48 h (%)
Median d
last pos
blood cu
(Rang
CVC removed
within 48 h
10 1 (20) 0 (0e
CVC not removed
within 48 h
32 7 (21.8) 0 (0eantibiogram did not show homology with the initial isolate, it is
unlikely to represent recrudescence of the initial infection. For
the remainder of recurrences, the antibiograms were indis-
tinguishable from the initial isolate. A CVC was the source in all
the patients who developed recurrence. The mean treatment
duration for initial SAB with IV or PO antibiotics likely to have
had some activity against the pathogen in 6 of the 7 patients
who developed recurrence was 11.2 days. The mean duration
of intravenous antibiotic treatment with an agent likely to have
some activity against the pathogen was 4.3 days. Four patients
had not received any optimal targeted SAB therapy at initial
presentation (i.e., had not received high dose IV flucloxacillin),
while two had each been treated for 3 days. In three out of six
cases, the CVC had not been removed at initial SAB diagnosis. In
the three cases where line removal was documented, the
median time from documented bacteraemia to line removal
was 3 days. In all cases, documented sterile blood cultures
were obtained following the initial SAB and the median time to
sterile blood cultures was 2 days. No complications or meta-
static foci of infection had been identified at initial pre-
sentation in any of the patients in whom recurrence occurred.Discussion
Our observations contribute new insights concerning the
management of SAB in oncology patients, albeit derived from
retrospective data and not a prospective study. The ethos of
prescribing antimicrobials in the ULHG onocology unit is
extremely judicious, only prescribing in response to the clinical
signs and symptoms exhibited by the patient and being ever
mindful of the sequelae associated with inappropriate pre-
scribing in patient already exposed to other toxic agents such
as chemotherapy. Likewise, there is strong emphasis on the
removal of possible sources of infection, such as intravascular
devices, in a timely manner.t removed within 48 hours or not removed at all
ays to
itive
lture
e)
Median days to
sterile blood
culture (Range)
Recurrence (%) Death due to SAB
2) 2 (1e8) 2 (40) 0
12) 2 (0e14) 5 (15.6) 1 (3.1)
Table 5
Antibiotic therapy in oncology patients with CVC SAB
Number of
episodes
Median days PO/IV
antibiotic likely to have
some activity (Range)
Median days IV antibiotic
likely to have activity
(Range)
Median days from line
removal to stopping PO/IV
antibiotic likely to have some
activity (Range)
Median days from line
removal to stopping IV
antibiotic likely to have
activity (Range)
CVC removed
within 48 h
9a 11 (8e41) 7 (2e14) 9 (7e40) 4 (0e12)
CVC removed
but not within
48 h
20 10 (6e14) 4.5 (0e10) 5.5 (0e11) 1 (0e10)
CVC salvaged 12 7 (2e27) 3 (0e13) - -
a One episode was excluded as palliative care was prioritised and antimicrobial therapy was not progressed.
C.P. Dunne et al. / Infection Prevention in Practice 2 (2020) 1000376Notably, our CVC removal rate was just 73% in SAB where
CVC was the identified source of infection, with an attributable
mortality rate far lower than would be expected. Furthermore,
antimicrobial therapy durations were considerably lower (10
days) than current recommendations of 14 days IV therapy [21].
The recurrence rate of 15% was also significantly lower than has
been reported in the literature previously [4].
It is important to consider that most prior studies have
described haematological malignancies accounting for a
greater portion of SAB cases [19,30]. In contrast, in our study
solid tumours were present in 98% of cases, with breast and
colorectal carcinoma accounting for the greatest proportion.
However, as stated, the prevalence of encountered cancers
closely represented Irish national prevalence data, with the
exception of lung carcinoma [29]. Indeed, this may be reflec-
tive of relatively low CVC insertion rates in lung carcinoma
patients and a comparatively poor prognosis. Although not
analysed in our study, advanced and progressive malignancies
have greater association with SAB [8].
Prior administration of chemotherapy seems an unlikely risk
factor given that most cases occurred at least 15 days following
the most recent chemotherapy delivered via CVC. Research
emphasis has frequently been placed on potential risk strat-
ification and identifying predictors of SAB mortality. Studies
have looked at multiple parameters including neutrophil
counts, tumour type, patient demographics and method of CVC
insertion [4,21,31,32]. Despite this emphasis, few parameters
have proven useful, with no standardised risk model available
currently. This is perhaps an indication of the complex nature
of oncology patient cohorts. Our current study found the neu-
trophil count to be a poor marker for bacteraemia in this
patient group. However, we did identify potential risk factors
in nearly half (42%) of cases; tentatively offering an approach
for high-risk categorization. It was striking that the risk factors
identified related mostly to prior S. aureus colonisation sug-
gesting a potential benefit of prophylactic decolonisation in
similar patient groups prior to or allied with CVC insertion. It is
equally arguable that, as shown by Stewart et al. (2016), good
CVC insertion technique and satisfactory line management may
provide the greatest potential for SAB risk reduction [33].
Throughout the period of this study, as detailed earlier, a
drug combination of piperacillin-tazobactam with or without
gentamicin was deemed appropriate empirical therapy.
Thereafter, intravenous flucloxacillin was recommended by the
microbiology clinical service when SAB was identified foroptimal treatment. Several studies have concluded that ß-
lactams, e.g. flucloxacillin, to be superior to glycopeptides,
namely vancomycin for treatment of MSSA bloodstream infec-
tions [5]. Flucloxacillin was further justified by the low
observed incidence of MRSA (8%) and awareness of local epi-
demiology in the oncology ward. Variation in patient charac-
teristic requires prudent choice of therapy as a similar study
from 2018 reported a MRSA prevalence of 21%, thus highlighting
the requirement for a pragmatic approach to drug choice [32].
Irrespective, despite a mean of only 2 days optimal therapy,
piperacillin-tazobactam with flucloxacillin proved both
appropriate and effective on the basis of determined mortality
and complication rates.
In that context, and as duration of antimicrobial therapy in
SAB patients remains a topic of interest [5,21,32], we deter-
mined our effective therapy duration to be 10 days but with IV
therapy duration of only 5 days. This contrasts with current
recommendation of 14 days IV therapy [5,6]. Importantly,
there was no evidence to support concerns of increased
recurrence, mortality and septic metastasis published pre-
viously [21]. Clearly though, further research in the form of
suitably powered prospective randomised controlled trials of
current recommendations versus our approach is needed to
assess whether the shorter duration of therapy is applicable
more broadly across malignancies and, specifically, in compli-
cated SAB.
In general, a paucity of studies has generated uncertainty as
to whether oral therapy is non-inferior to IV therapy in this
setting. Our findings indicate that relatively early adoption of
oral administration following 5 days of IV therapy may be
effective. This observation complements a statement in Dutch
guidelines that “.safety and efficacy of an early switch from
intravenous to oral antibiotics (mostly quinolones) can prob-
ably be extrapolated to other antimicrobial agents with high
bioavailability .” (https://www.swab.nl/swab/cms3.nsf/
uploads/65FB380648516FF2C125780F002C39E2/$FILE/swab_
sepsis_guideline_december_2010.pdf) and the results of two
published RCTs in which oral therapy alone was found to be
equally as successful in achieving cure as IV therapy [12,13].
Therefore, it seems reasonable to suggest that a greater use of
oral therapy in SAB may decrease hospital length of stay and
reduce associated healthcare costs. However, a prospective
appropriately-designed study would be needed to validate this
approach. Although outside the scope of this study, it may be
useful to assess early adoption of oral therapy in the outpatient
C.P. Dunne et al. / Infection Prevention in Practice 2 (2020) 100037 7setting, leading perhaps to a reduced requirement for nurse
visits for outpatient parental antimicrobial therapy (OPAT) IV
administration and/or a lesser need for patient self-
administration of IV in favour of oral antimicrobial use.
As shown, albeit that our cohort size was limited, the
attributable mortality rate in our study (<4%) was markedly
lower than that reported in similar patient groups. Bello-
Chavolla et al. reported a mortality rate of 17% while Edge-
worth reported a rate of 33% [4,32]. Furthermore, our observed
rate of recurrence, at 15%, was lower than expected compared
with Edgeworth’s rate of 23% under similar circumstances [4].
Given that our figures were achieved utilising shortened ther-
apy durations, it poses the question whether current recom-
mendations for SAB management are appropriate. This
question is equally valid as our practice did not involve uni-
versal line removal in CVC source SAB despite current guide-
lines and recent report recommending prompt removal when
possible, [5,14,21,30,31] albeit that this was due to individual
patient-related factors and potential benefits of salvaging CVCs
as reported elsewhere [34,35]. Overall, albeit derived from an
analysis of retrospective data, this study suggests that there
may be merit in pursuing a prospective study comparing our
approach with currently-recommended CVC removal and 14
days of IV therapy to determine whether patients would benefit
from a more individualised therapeutic approach. Such an
approach may, ideally, reflect patient characteristics and take
into consideration the complex nature of oncology patients
allowing, perhaps, for the potential of personalised medicine
and care based on cancer type, concomitant therapy and
microorganisms involved.
Funding
This work was supported in part by the University of Lim-
erick Graduate Entry Medical School summer research stu-
dentship programme.
Author contributions
CPD, NHOC and RG contributed to analysis and inter-
pretation of data, recognition of novel information, and
drafting of the manuscript. PR, RC, MK, SSD and JP contributed
to analysis and interpretation of data and drafting the manu-
script. MK, RC and NHOC reviewed the patient records. All
authors have reviewed and approve the manuscript.
Declaration of Competing Interest
The authors declare no competing personal or financial
interests and have nothing to disclose.
References
[1] Kaasch AJ, Barlow G, Edgeworth JD, Fowler Jr VG, Hellmich M,
Hopkins S, et al. Staphylococcus aureus bloodstream infection: A
pooled analysis of five prospective, observational studies. Journal
of Infection 2014;68(3):242e51.
[2] Health Protection Surveillance Centre. http://www.hpsc.ie/AZ/
MicrobiologyAntimicrobialResistance/
EuropeanAntimicrobialResistanceSurveillanceSystemEARSS/
ReferenceandEducationalResourceMaterial/SaureusMRSA/
LatestSaureusMRSAdata/; 2018.[3] Liu C, Strnad L, Beekmann SE, Polgreen PM, Chambers HF. Clinical
practice variation among adult infectious diseases physicians in
the management of Staphylococcus aureus bacteremia. Clinical
Infectious Diseases 2019;69(3):530e3.
[4] Edgeworth J. Intravascular catheter infections. Journal of Hos-
pital Infection 2009;73(4):323e30.
[5] Thwaites GE, Edgeworth JD, Gkrania-Klotsas E, Kirby A,
Tilley R, Torok ME, et al. Clinical management of Staph-
ylococcus aureus bacteraemia. Lancet Infectious Diseases
2011;11(3):208e22.
[6] Holland TL, Arnold C, Fowler VG. Clinical management of
Staphylococcus aureus bacteremia: A review. JAMA - Journal of
the American Medical Association 2014;312(13):1330e41.
[7] Asgeirsson H, Kristjansson M, Kristinsson KG, Gudlaugsson O.
Staphylococcus aureus bacteraemia - Nationwide assessment of
treatment adequacy and outcome. Journal of Infection
2011;62(5):339e46.
[8] Carney DN, Fossieck Jr BE, Parker RH, Minna JD. Bacteremia due
to Staphylococcus aureus in patients with cancer: Report on 45
cases in adults and review of the literature. Reviews of Infectious
Diseases 1982;4(1):1e12.
[9] Siegman-Igra Y, Reich P, Omi-Wasserlauf R, Schwartz D, Giladi M.
The role of vancomycin in the persistence or recurrence of
Staphylococcus aureus bacteraemia. Scandinavian Journal of
Infectious Diseases 2005;37(8):572e8.
[10] Khatib R, Johnson LB, Fakih MG, Riederer K, Khosrovaneh A,
Shamse Tabriz M, et al. Persistence in Staphylococcus aureus
bacteremia: Incidence, characteristics of patients and outcome.
Scandinavian Journal of Infectious Diseases 2006;38(1):7e14.
[11] Stryjewski ME, Szczech LA, Benjamim Jr DK, Inrig JK,
Kanafani ZA, Engemann JJ, et al. Use of vancomycin or first-
generation cephalosporins for the treatment of hemodialysis-
dependent patients with methicillin-susceptible Staphylococcus
aureus bacteremia. Clinical Infectious Diseases
2007;44(2):190e6.
[12] Heldman AW, Hartert TV, Ray SC, Daoud EG, Kowalski TE,
Pompili VJ, et al. Oral antibiotic treatment of right-sided staph-
ylococcal endocarditis in injection drug users: Prospective
randomized comparison with parenteral therapy. American
Journal of Medicine 1996;101(1):68e76.
[13] Schrenzel J, Harbarth S, Schockmel G, Genne´ D, Bregenzer T,
Flueckiger U, et al. A randomized clinical trial to compare
fleroxacin-rifampicin with flucloxacillin or vancomycin for the
treatment of staphylococcal infection. Clinical Infectious Dis-
eases 2004;39(9):1285e92.
[14] Burnham JP, Rojek RP, Kollef MH. Catheter removal and out-
comes of multidrug-resistant central-line-associated bloodstream
infection. Medicine 2018;97(42):e12782.
[15] Johnson LB, Almoujahed MO, Ilg K, Maolood L, Khatib R. Staph-
ylococcus aureus bacteremia: Compliance with standard treat-
ment, long-term outcome and predictors of relapse. Scandinavian
Journal of Infectious Diseases 2003;35(11):782e9.
[16] Price J, Baker G, Heath I, Walker-Bone K, Cubbon M, Curtis S,
et al. Clinical and microbiological determinants of outcome in
Staphylococcus aureus bacteraemia. International Journal of
Microbiology 2010;2010:654858. https://doi.org/10.1155/2010/
654858.
[17] Fowler Jr VG, Olsen MK, Corey GR, Woods CW, Cabell CH,
Reller LB, et al. Clinical identifiers of complicated Staphylococcus
aureus bacteremia. Archives of Internal Medicine
2003;163(17):2066e72.
[18] Gonza´lez-Barca E, Carratala J, Mykietiuk A, Ferna´ndez-Sevilla A,
Gudiol F. Predisposing factors and outcome of Staphylococcus
aureus bacteremia in neutropenic patients with cancer. European
Journal of Clinical Microbiology and Infectious Diseases
2001;20(2):117e9.
[19] Kang CI, Song JH, Chung DR, Peck KR, Yeom JS, Son JS, et al.
Bloodstream infections in adult patients with cancer: Clinical
C.P. Dunne et al. / Infection Prevention in Practice 2 (2020) 1000378features and pathogenic significance of Staphylococcus aureus
bacteremia. Supportive Care in Cancer 2012;20(10):2371e8.
[20] Ghanem GA, Boktour M, Warneke C, Pham-Williams T, Kassis C,
Bahna P, et al. Catheter-related Staphylococcus aureus bacter-
emia in cancer patients: High rate of complications with ther-
apeutic implications. Medicine 2007;86(1):54e60.
[21] Wolf HH, Leithauser M, Maschmeyer G, Salwender H, Klein U,
Chaberny I, et al. Central venous catheter-related infections in
hematology and oncology: : guidelines of the Infectious Diseases
Working Party (AGIHO) of the German Society of Hematology and
Oncology(DGHO). Annals of Hematology 2008;87(11):863e76.
[22] Zeylemaker MMP, Jaspers CA, van Kraaij MG, Visser MR,
Hoepeiman IM. Long-term infectious complications and their
relation to treatment duration in catheter-related Staph-
ylococcus aureus bacteremia. European Journal of Clinical
Microbiology & Infectious Disease 2001;20(6):380e4.
[23] Le Moing V, Alla F, Doco-Lecompte T, Delahaye F, Piroth L,
Chirouze C, et al. Staphylococcus aureus bloodstream infection
and endocarditis - A prospective cohort study. PLoS ONE
2015;10(5):e0127385. https://doi.org/10.1371/
journal.pone.0127385.
[24] Raad I, Narro J, Khan A, Tarrand J, Vartivarian S, Bodey GP.
Serious complications of vascular catheter-related Staph-
ylococcus aureus bacteremia in cancer patients. European Jour-
nal of Clinical Microbiology & Infectious Diseases
1992;11(8):675e82.
[25] O’Connor C, Powell J, Finnegan C, O’Gorman A, Barrett S,
Hopkins KL, et al. Incidence, management and outcomes of the
first cfr-mediated linezolid-resistant Staphylococcus epidermidis
outbreak in a tertiary referral centre in the Republic of Ireland.
Journal of Hospital Infection 2015;90(4):316e21.
[26] O’Connor C, Cormican M, Boo TW, McGrath E, Slevin B,
O’Gorman A, et al. An Irish outbreak of New Delhi metallo-beta-
lactamase (NDM)-1 carbapenemase-producing Enter-
obacteriaceae: increasing but unrecognized prevalence. Journal
of Hospital Infection 2016a;94(4):351e7.
[27] O’Connor C, Philip RK, Kelleher J, Powell J, O’Gorman A,
Slevin B, et al. The first occurence of a CTX-M ESBL-producingEscherichia coli outbreak mediated by mother to neonate trans-
mission in an Irish neonatal intensive care unit. BMC Infectious
Disease 2017;17(1):16. https://doi.org/10.1186/s12879-016-
2142-6.
[28] O’Connor C, Philip RK, Powell J, Slevin B, Quinn C, Power L, et al.
Combined education and skin antisepsis intervention for persis-
tently high blood-culture contamination rates in neonatal inten-
sive care. Journal of Hospital Infection 2016b;93(1):105e7.
[29] Irish Department of Health Health. Cancer in Ireland 1994-2016
with estimates for 2016-2018: Annual Report of the National
Cancer Registry. Available at: https://www.ncri.ie/sites/ncri/
files/pubs/annualreport2018_26112018.pdf; 2018.
[30] El Zakhem A, Chaftari AM, Bahu R, El Helou G, Shelburne S,
Jiang Y, et al. Central line-associated bloodstream infections
caused by Staphylococcus aureus in cancer patients: Clinical
outcome and management. Annals of Medicine 2014;46(3):163e8.
[31] Bassetti M, Peghin M, Trecarichi EM, Carnelutti A, Righi E, Del
Giacomo P, et al. Characteristics of Staphylococcus aureus bac-
teraemia and predictors of early and late mortality. PLoS ONE
2017;12(2):e0170236. https://doi.org/10.1371/
journal.pone.0170236.
[32] Bello-Chavolla OY, Bahena-Lopez JP, Garciadiego-Fosass P,
Volkow P, Garcia-Horton A, Velazquez-Acosta C, et al. Blood-
stream infection caused by S. aureus in patients with cancer: a
10-year longitudinal single-center study. Supportive Care in
Cancer 2018;26(12):4057e65.
[33] Stewart BJ, Gardiner T, Perry GJ, Tong SY. Reduction in Staph-
ylococcus aureus bacteraemia rates in patients receiving hae-
modialysis following alteration of skin antisepsis procedures.
Journal of Hospital Infection 2016;92(2):191e3.
[34] Chaftari P, Chaftari AM, Adachi J, Hachem R, Raad S, Natividad E,
et al. Improvement in the diagnosis of catheter-related blood-
stream infections in a tertiary cancercenter. American Journal of
Infection Control 2017;45(3):e34e9.
[35] Chaftari AM, Hachem R, Raad S, Jiang Y, Natividad E, Chaftari P,
et al. Unnecessary removal of central venous catheters in cancer
patients with bloodstream infections. Infection Control & Hospi-
tal Epidemiology 2018;39(2):222e5.
